Actemra vs. other biologic response modifiers
Actemra vs. other biologic response modifiers
| Actemra vs. other biologic response modifiers | ||||
| Actemra tocilizumab appears to be more effective than other biologic response modifiers marketed to treat rheumatoid arthritis, based on updated data presented at the American College of Rheumatology meeting last week. If approved, the humanized monoclonal antibody would be the |
